Affordable Access

deepdyve-link
Publisher Website

Maintenance of Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Randomized-Withdrawal Study Design

Authors
  • Coghill, David R.
  • Banaschewski, Tobias
  • Lecendreux, Michel
  • Johnson, Mats
  • Zuddas, Alessandro
  • Anderson, Colleen S.
  • Civil, Richard
  • Dauphin, Matthew
  • Higgins, Nicholas
  • Lyne, Andrew
  • Gasior, Maria
  • Squires, Liza A.1, 2, 3, 4, 5, 6, 7
  • 1 University of Dundee
  • 2 Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg
  • 3 Pediatric Sleep Center, Hôpital Universitaire Robert Debré
  • 4 Queen Silvia Children's Hospital
  • 5 University of Cagliari
  • 6 Shire Development LLC
  • 7 Shire Pharmaceutical Development Ltd
Type
Published Article
Journal
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier
Publication Date
Jan 01, 2014
Accepted Date
Feb 28, 2014
Identifiers
DOI: 10.1016/j.jaac.2014.01.017
Source
Elsevier
Keywords
License
Unknown

Abstract

ObjectiveIn this phase 3 extension study, the long-term maintenance of efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) was evaluated using a randomized-withdrawal study design. MethodEuropean and US patients (6–17 years; N = 276) with ADHD were entered into a 26-week open-label trial of LDX treatment. Those who completed the open-label period (n = 157) were randomized 1:1 to their optimized dose of LDX (30, 50, or 70 mg per day) or placebo for a 6-week randomized-withdrawal period (RWP). The primary efficacy measure was the proportion of patients meeting treatment failure criteria (≥50% increase in ADHD Rating Scale IV total score and ≥2-point increase in Clinical Global Impressions–Severity of Illness (CGI-S) score, compared with RWP start point). Safety and tolerability were also evaluated. ResultsDuring the RWP (LDX, n = 78; placebo, n = 79), significantly fewer patients receiving LDX met treatment failure criteria (15.8%) compared with those receiving placebo (67.5%; difference = –51.7%; 95% confidence interval = –65.0, –38.5; p < .001 ). Most treatment failures occurred at or before the week 2 visit after randomization. Treatment-emergent adverse events were reported in 39.7% and 25.3% of patients receiving LDX and placebo, respectively, during the RWP. ConclusionsThese data demonstrate the maintenance of efficacy of LDX during long-term treatment in children and adolescents with ADHD. The rapid return of symptoms on LDX withdrawal demonstrates the need for continuing treatment. The safety profile of LDX was consistent with that of other stimulants.Clinical trial registration information—Double-Blind, Placebo-Controlled, Randomized Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17; http://clinicaltrials.gov; NCT00784654.

Report this publication

Statistics

Seen <100 times